 |
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
|
Hepregen
reels in $500k SBIR award
Hepregen Corp. has won a $500,000 Phase 2 SBIR grant from the National Science Foundation, contributing to the company’s total $2 million in federal funding.
The Medford-based company is developing a platform to reduce the liver toxicity caused by approved drugs. The SBIR grant funds will be used on a project, “Development of a Human Liver Platform for High-Throughput Screening of Drug-Induced Liver Injury and Drug-Drug Interaction”, led by director of research Salman Khetani
The platform is based on technology developed by 2009 Mass High Tech Woman to Watch Sangeeta Bhatia, a professor in the Harvard-MIT Division of Health Sciences and Technology and MIT’s Department of Electrical Engineering and Computer Science. The technology is based on engineered “miniature micro liver cells.”
Hepregen was co-founded in 2007 by Bhatia, Khetani, and Bernadette Fendrock, president and CEO of the company.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|